Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 621-626

  Hall, G D ^a,e   Brown, J M ^b   Coleman, R E ^c   Stead, M ^b   Metcalf, K S ^d   Peel, K R ^e   Poole, C ^f   Crawford, M ^g   Hancock, B ^c   Selby, P J ^a   Perren, T J ^a,e  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d PRINCESS ANNE HOSPITAL   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f CITY HOSPITAL   (United Kingdom)

^g AIREDALE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Interferon alpha; Maintenance therapy; Ovarian cancer

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANXIETY DISORDER; ARTHRALGIA; ARTHRITIS; ARTICLE; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GYNECOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE; INSOMNIA; LIVER DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; NEUROLOGIC DISEASE; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; TOXICITY; UNITED KINGDOM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MIDDLE AGED; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 4344703324     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602037     Document Type: Article

References (16)

1. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD (1985) Intraperitoneal recombinant alpha-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res 45: 4447-4453
2. Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D (1999) Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 75: 10-14
3. Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, Giannessi PG, Carnino F, Iskra L, Rosso R, Martoni A, Pannuti F, De LV, Maltoni R, Ridolfi R, Mammoliti S, Gallo L, Boccardo F, Ragni N, Conte PF (1997) Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 65: 499-505
4. Einhorn N, Ling P, Einhorn S, Strander H (1988) A phase II study on escalating interferon doses in advanced ovarian carcinoma. Am J Clin Oncol 11: 3-6
5. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Blumenson LE (1998) Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 71: 190-195
6. Epstein LB, Shen JT, Abele JS, Reese CC (1980) Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique. Ann NY Acad Sci 350: 228-244
7. Freedman RS, Gutterman JU, Wharton JT, Rutledge FN (1983) Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Resp Mod 2: 133-138
8. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430-1434
9. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460-2465
10. McGuire WP (2000) High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol 27: 41-46
11. Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F (1990) Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 8: 1036-1041
12. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14: 343-350
13. Thigpen JT, Vance RB, Lambuth BW (1988) Ovarian carcinoma: the role of chemotherapy. Semin Oncol 15: 16-23
14. Umesaki N, Tanaka T, Muso H, Kawamura N, Kanaoka Y, Honda K, Deguchi M, Ishiko O, Ogita S (1999) Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission. Gynecol Obstet Invest 47: 139-143
15. Willemse PH, de Vries EG, Mulder NH, Aalders JG, Bouma J, Sleijfer DT (1990) Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 26: 353-358
16. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: 1138-1144